康诺亚与Aeira签署司普奇拜单抗东南亚及中亚18国独家商业化许可协议

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT – ENTERED INTO A LICENSING
AGREEMENT IN RELATION TO THE MARKETING REGISTRATION
AND COMMERCIALIZATION OF STAPOKIBART INJECTION IN 18
COUNTRIES AND REGIONS INCLUDING SOUTHEAST ASIA AND
CENTRAL ASIA
This announcement is made by Keymed Biosciences Inc. (the “Company” or “Keymed”, together
with its subsidiaries, the “Group”) on a voluntary basis to inform the shareholders and potential
investors of the Company of the latest business development of the Group.
Keymed entered into an exclusive licensing agreement with multinational pharmaceutical
company Aeira Pte. Ltd. (“Aeira”). Both parties will collaborate on the marketing registration
and commercialization of the IL-4Rα-targeted monoclonal antibody independently developed by
Keymed, Stapokibart injection (trade name: Kangyueda®), in Southeast Asia and Central Asia.
Pursuant to the agreement, Keymed will receive an upfront payment, as well as milestone payments
upon the approval of marketing applications in various countries and commercialization milestone
payments, and is entitled to receive royalties of up to a high double-digit percentage based on the
net sales of the product in the licensed territory.
Aeira will be responsible for the registration filings and commercialization matters of Stapokibart
injection in a total of 18 countries and regions, including 11 countries in the Southeast Asia
region (Brunei Darussalam, Cambodia, Indonesia, Lao People’s Democratic Republic, Malaysia,
Myanmar, the Philippines, Singapore, Thailand, Timor-Leste and Vietnam) and 5 countries in the
Central Asia region (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan), as well
as the Hong Kong Special Administrative Region and the Macao Special Administrative Region.
Keymed will continue to be responsible for the manufacture and product supply of Stapokibart
injection for Aeira.
This collaboration represents an important milestone in the internationalization strategy for
innovative biological drugs of Keymed. Leveraging the partner ’ s unique commercial network
and registration experience in Southeast Asia, Central Asia and other regions, it will accelerate
the launch and commercialization process of Stapokibart in the aforementioned regions, further
enhancing the global accessibility of the Company’s innovative products and benefiting more
patients.

1

ABOUT STAPOKIBART
Stapokibart (trade name: Kangyueda®, R&D codename: CM310) is a high-efficient, humanized
antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically
manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4
and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has demonstrated
good safety and encouraging efficacy in multiple previous clinical trials, and its treatment of the
indication of moderate-to-severe atopic dermatitis in adults, the indication of chronic rhinosinusitis
with nasal polyposis and the indication of seasonal allergic rhinitis have been approved for
marketing in September 2024, December 2024 and February 2025, respectively.
RISK WARNING
Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company
and its collaborators will ultimately succeed in developing, listing and/or commercializing
Stapokibart in Southeast Asia, Central Asia, the Hong Kong Special Administrative Region and the
Macao Special Administrative Region. Shareholders and potential investors of the Company are
advised to exercise caution when dealing in the shares of the Company.
By order of the Board
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman
Hong Kong, September 2, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Bo CHEN, Dr.
Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG
and Mr. Yilun LIU as non-executive Directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and
Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.

2

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性
或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴
該等內容而引致之任何損失承擔任何責任。

Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
（於開曼群島註冊成立的有限公司）

（股份代號：2162）

自願性公告 － 就司普奇拜單抗注射液東南亞和
中亞等18個國家和地區上市註冊和商業化達成許可協議
本公告乃由康諾亞生物醫藥科技有限公司（「本公司」或「康諾亞」，連同其附屬公
司「本集團」）自願作出，以告知本公司股東及潛在投資者有關本集團的最新業務
進展。
康諾亞與跨國醫藥公司Aeira Pte. Ltd.（Aeira）簽署獨家許可協議。雙方將就康諾
亞自主研發的靶向IL-4Rα的單克隆抗體 —— 司普奇拜單抗注射液（商品名：康悅
達 ®）在東南亞和中亞地區的上市註冊和商業化展開合作。
根據協議，康諾亞將獲得首付款以及不同國家上市申請獲批的里程碑付款及商業
化里程碑付款，並有權利收取基於許可區域產品淨銷售額計算高達高雙位數率的
特許權使用費。
Aeira將負責司普奇拜單抗注射液在東南亞地區（文萊達魯薩蘭國、柬埔寨、印度
尼西亞、老撾人民民主共和國、馬來西亞、緬甸、菲律賓、新加坡、泰國、東帝
汶、越南）11個國家和中亞地區（哈薩克斯坦、吉爾吉斯斯坦、塔吉克斯坦、土庫
曼斯坦、烏茲別克斯坦）5個國家，以及香港特別行政區和澳門特別行政區等共計
18個國家和地區的註冊申報以及商業化事宜。康諾亞將持續為Aeira負責司普奇拜
單抗注射液的生產和產品供應。
本次合作是康諾亞創新生物藥國際化戰略的重要里程碑，將借助合作方在東南亞
及中亞等地區獨特的商業網絡和註冊經驗，加快司普奇拜單抗在上述區域的上市
及商業化進程，進一步提升本公司創新產品的全球可及性，惠及更多患者。

1

關於司普奇拜單抗
司普奇拜單抗（商品名：康悅達 ®，研發代號：CM310）是一種針對白介素4受體α
亞基(IL-4Rα)的高效、人源化抗體，其為首個國產且獲得中國國家藥品監督管理
局批准上市的IL-4Rα抗體藥物。通過靶向IL-4Rα，司普奇拜單抗可雙重阻斷白介
素4(IL-4)及白介素13(IL-13)的信號傳導。IL-4及IL-13為引發II型炎症的兩種關鍵
細胞因子。司普奇拜單抗已在過往多項臨床試驗中，顯示了良好的安全性及令人
鼓舞的療效，其治療成人中重度特應性皮炎的適應症已於2024年9 月獲批上市，
治療慢性鼻竇炎伴鼻息肉的適應症已於2024年12月獲批上市，治療季節性過敏性
鼻炎的適應症已於2025年2月獲批上市。

風險提示
香港聯合交易所有限公司證券上市規則第18A.08(3)條規定的提示聲明：本公司並
不保證本公司及其合作方最終將在東南亞地區、中亞地區以及香港特別行政區和
澳門特別行政區成功開發、上市及 ╱ 或商業化司普奇拜單抗。本公司股東及潛在
投資者於買賣本公司股份時務請審慎行事。
承董事會命
康諾亞生物醫藥科技有限公司
董事長
Bo CHEN博士
香港，2026年9月2日

於本公告日期，本公司董事會包括執行董事Bo CHEN博士、Changyu WANG博士
及徐剛博士；非執行董事陳奇先生、王閩川博士及劉逸倫先生；及獨立非執行董
事王小凡教授、柯楊教授及羅卓堅先生。

2